35414 - Multiple Sclerosis: Drugs (Answered)

Simon Hoare
To ask the Secretary of State for Health, pursuant to the Answer of 22 February 2016 to Question 26606, whether it is his Department's intention that all patients diagnosed with multiple sclerosis will have access to the drugs previously covered by the Risk Sharing Scheme (a) until and (b) beyond the conclusion of the NICE Multiple Sclerosis MTA in 2017.

George Freeman

The Multiple Sclerosis Risk-Sharing Scheme will remain in place until the publication of the National Institute for Health and Care Excellence’s (NICE) final updated technology appraisal guidance on disease modifying therapies for the treatment of multiple sclerosis.

As long as they are clinically eligible, new and existing patients can continue to access these therapies as part of the Scheme.

Once NICE’s appraisal has been completed, the normal access arrangements will apply. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE within three months of NICE’s guidance being published. In the absence of a positive recommendation from NICE, it is for commissioners to make decisions on whether to fund treatments based on an assessment of the available evidence.